alexa Examination of the FDA Warning for Statins and Cognitive Dysfunction

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Examination of the FDA Warning for Statins and Cognitive Dysfunction

Statins are widely prescribed in the United States for primary and secondary cardiovascular risk reduction and constitute an estimated $26 billion dollar per year market for pharmaceutical manufacturers . The numbers of patients receiving statin therapy is likely to increase in the coming years based on the dissemination in 2013 of the American College of Cardiology/American Heart Association’s (ACC/AHA) updated clinical guidelines for the assessment and management of blood cholesterol for primary and secondary prevention . Although the new guidelines simplify clinical treatment strategies, they promote a broader risk assessment tool which may increase the numbers of patients between the ages of 20 – 79 eligible for statin use for primary prevention to an estimated 46 million Americans .

Citation: Sahebzamani FM, Munro CL, Marroquin OC, Diamond DM, Keller E, et al. (2014) Examination of the FDA Warning for Statins and Cognitive Dysfunction. J Pharmacovigilance 2:141.

 
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
 
adwords